Abstract 901P
Background
Chemoradiation (CRT) in patients (pts) with locally advanced head and neck squamous cell cancer (HNSCC) is associated with significant toxicities, including oral mucositis (OM). The gut microbiome (GM) is an emerging biomarker of treatment outcomes and adverse events. This study aimed to investigate the role of GM composition to predict CRT toxicities in HNSCC pts, including development of severe OM.
Methods
We prospectively collected fecal samples of 52 pts with HNSCC undergoing CRT. Using shotgun metagenomic sequencing and MetaPhlAn4 pipeline, LefSe differences in GM composition at baseline were assessed according to CTCAE v4.0 toxicity grading including OM and enteral feeding tube requirement. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method.
Results
Most tumors (n=40) were p16-positive, including oropharyngeal (n=35) and unknown primaries (n=4). TNM staging was III-IV in 54% (n=28). After a median follow-up of 27 mo, the 12-mo OS and PFS were 96% and 84%, respectively. In terms of toxicity, OM was seen in all pts, and 22 pts (42%) developed grade ≥3 OM. Thirteen pts (25%) required enteral feeding. Grade ≥3 OM was associated with a significant decrease in OS (p=0.02) even when accounting for staging and p16 status in multivariate analysis (MVA; p<0.05), as well as a numerically shorter PFS (p=0.09). No baseline characteristic correlated with increased risk of severe OM in MVA. However, GM beta-diversity differed between grade 1-2 and grade 3 OM (PERMANOVA p=0.04) but there was no difference in alpha-diversity. Pts with severe OM had distinct GM enriched with Mediterraneibacter (Ruminococcus gnavus) and members of the Clostridiaceae family, including Hungatella hathewayi. In pts with mild OM, Eubacterium rectale, Alistipes putredinis and members of the Ruminococcaceae family were overrepresented. We observed similar microbiome differences in pts requiring enteral feeding.
Conclusions
Severe OM was associated with decreased OS and PFS in pts with HNSCC undergoing CRT. Pts who developed severe OM or required enteral feeding had a distinct GM enriched with deleterious bacteria that have been associated with resistance to immune checkpoint inhibitors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Oncobiome grant #825410.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
878P - INHBA is overexpressed in HPV-negative oropharyngeal squamous cell carcinoma and contributes to an aggressive phenotype
Presenter: Simon Laban
Session: Poster session 12
880P - ctHPV16-DNA in Liquid Biopsy: A promising biomarker to monitor disease status in patients with HPV-positive oropharyngeal squamous cell carcinoma
Presenter: Nora Würdemann
Session: Poster session 12
881P - SOTO study: Prospective study to correlate the treatment sensitivity of patient-derived organoids (PDOs) with treatment outcomes in head and neck cancer patients
Presenter: Ifigenia Vasiliadou
Session: Poster session 12
882P - Claudin-1 (CLDN1) expression in head and neck squamous cell carcinoma (HNSCC) patients
Presenter: Stefano Cavalieri
Session: Poster session 12
884P - Prognostic value and immune characteristics of LGALS1 in head and neck squamous cell carcinoma
Presenter: Yanfei Min
Session: Poster session 12
885P - Clinical significance of folate receptor-positive circulating tumor cells detected by ligand-targeted polymerase chain reaction in nasopharyngeal carcinoma
Presenter: Dingyi Wang
Session: Poster session 12
887P - Antitumor activity of the radioenhancer NBTXR3 on injected lesions to estimate overall survival: Exploratory analyses from a phase I in cisplatin-ineligible locally advanced HNSCC patients
Presenter: Christophe Le Tourneau
Session: Poster session 12
888P - Phase I study of olaparib combined with loco-regional radiotherapy in patients with head and neck squamous cell carcinoma
Presenter: Marcel Verheij
Session: Poster session 12